Skip to main content
MyChart News! ¡Noticias de MyChart!

Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now

¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.

Important Update Actualización importante:

Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!

¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!

Updated Prior Authorization Criteria for Breyanzi

Date: November 16, 2026

Attention: All Providers

Effective date: December 1, 2026

Call to action: Texas Children's Health Plan (TCHP) would like to inform providers that effective for dates of service on or after December 1, 2026, Texas Medicaid will update the prior authorization criteria for lisocabtagene maraleucel (Breyanzi) (procedure code Q2054).

The U.S. Food & Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for adult patients with relapse or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

Updated Prior Authorization Requirements

Prior authorization may be approved for lisocabtagene maraleucel (Breyanzi) infusion therapy when the adult patient meets one of the following diagnosis criteria:

  • The patient has relapse or refractory mantle cell lymphoma (MCL) and received at least two prior lines of systemic therapy, including Bruton tyrosine kinase (BTK) inhibitor.
  • The patient has relapse or refractory MZL and at least one of the following has occurred:
    • The patient received at least two prior lines of systemic therapy (including an anti-CD20 antibody and alkylating agent).
    • The patient has relapsed after hematopoietic stem cell transplantation (HSCT).

Reimbursement

The Texas Medicaid & Healthcare Partnership (TMHP) may reimburse claims for lisocabtagene maraleucel (Breyanzi) (procedure code Q2054) when they are submitted with the additional diagnosis code C8840.

Next step for providers: Providers should share this information with their staff.

If you have any questions, please email Provider Relations at providerrelations@texaschildrens.org.

For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.